Bristol Myers Squibb announced this weekend the results of a phase 3 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus investigator-selected chemotherapy (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) as first-line treatment for patients with metastatic colorectal cancer (mCRC).

Dual immunotherapy combining Opdivo and Yervoy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), with a 79% reduction in the risk of disease progression or death compared to chemotherapy.

These late-breaking data were presented at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal Cancers Symposium on Saturday, January 20.

Copyright (c) 2024 CercleFinance.com. All rights reserved.